Pulse Biosciences, Inc. (PLSE)
| Market Cap | 1.77B +50.0% |
| Revenue (ttm) | 751,000 |
| Net Income | -74.57M |
| EPS | -1.10 |
| Shares Out | 69.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 364,270 |
| Open | 26.19 |
| Previous Close | 25.45 |
| Day's Range | 25.38 - 26.42 |
| 52-Week Range | 12.56 - 28.53 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 30.67 (+19.81%) |
| Earnings Date | May 4, 2026 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PLSE stock is "Strong Buy." The 12-month stock price target is $30.67, which is an increase of 19.81% from the latest price.
News
Pulse Biosciences Transcript: AGM 2026
The meeting confirmed strong financials, new leadership appointments, and strategic focus on completing the pivotal AFib trial ahead of schedule. All director nominees were elected and the auditor ratified, with no shareholder questions submitted.
Pulse Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted a differentiated nanosecond PFA platform with strong clinical data, a focused AFib strategy, and a partner-driven commercial approach. Regulatory milestones are ahead of schedule, with launch targeted for early 2028 and robust financial positioning supporting execution.
Pulse Biosciences announces planned redemption of warrants
Pulse Biosciences (PLSE) intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part…
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Canaccord starts Pulse Biosciences with Buy on ablation potential
Canaccord initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $32 price target The company has a “differentiated” cardiac ablation platform to meet the needs of electrophysiologists, ...
Pulse Biosciences initiated with a Buy at Canaccord
Canaccord initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $32 price target
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to p...
Pulse Biosciences Transcript: Bank of America Global Healthcare Conference 2026
The conference highlighted advances in nanosecond pulsed field ablation, strong clinical results in AFib, and accelerated pivotal study enrollment. Leadership and IP position support expansion into new markets, with a focus on capital efficiency and execution through 2027.
Pulse Biosciences Slides: Corporate presentation
Pulse Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pulse Biosciences announces ATM equity purchases by co-chairmen
Pulse Biosciences (PLSE) announced its Co-Chairmen of the Board, Robert Duggan and CEO Paul LaViolette, completed purchases of Pulse Biosciences’ common stock through its at-the-market equity offering...
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Cha...
Pulse Biosciences Proxy statement: Proxy filing
Pulse Biosciences filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to p...
Pulse Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 marked a pivotal quarter with accelerated clinical progress, strong feasibility data, and a sharpened focus on the nPulse cardiac catheter program. Financials showed increased investment in clinical trials, with ample liquidity to fund operations through key milestones.
Pulse Biosciences Earnings release: Q1 2026
Pulse Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Pulse Biosciences Quarterly report: Q1 2026
Pulse Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Pulse Biosciences reports Q1 EPS (27c) vs (25c) last year
Reports Q1 revenue $401k. “This was a defining quarter for Pulse Biosciences (PLSE). We sharpened our strategic focus on electrophysiology based on landmark clinical outcomes that reinforced the durab...
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, t...
Pulse Biosciences presents clinical data from nPulse Cardiac Catheter System
Pulse Biosciences (PLSE) announced late-breaking “positive” clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings ...
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, t...
Pulse Biosciences to feature nPulse tech at Heart Rhythm Society meeting
Pulse Biosciences (PLSE) announced that its nPulse Cardiac Catheter will be prominently featured during the Heart Rhythm Society 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At ...
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its ...
Pulse Biosciences to Host Analyst Event on April 25, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to h...
Pulse Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing proprietary nanosecond pulsed field ablation technology, targeting rapid, efficient AFib treatment with a single catheter system. Strong clinical data, robust IP, and a solid financial position support accelerated IDE enrollment and expansion into new indications, with pivotal regulatory milestones expected by early 2028.
Pulse Biosciences Slides: Corporate presentation
Pulse Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.